U.S. Agency Warns Company Marketing ‘Stem Cells’ for Autism
December 16, 2019
(Spectrum) – The U.S. Food and Drug Administration (FDA) has over the past week taken multiple actions against makers of stem-cell products. On 5 December, the agency warned California-based Liveyon that its unapproved stem cell products “put patients at risk” due to the possibility of microbial contamination. On 9 December, the agency issued a safety alert, warning the public about unapproved products based on stem cells and exosomes — membrane-bound sacs that shuttle molecules between cells.